Year-Long test for rare brain disease treatment
NCT ID NCT06235775
Summary
This study followed patients for an extra year to check the long-term safety and see if the drug GV1001 continued to help control Progressive Supranuclear Palsy (PSP), a rare and serious brain disorder. It involved 67 patients who had already completed a previous trial, giving them regular injections under the skin. The main goal was to monitor for side effects and track blood test results over the extended treatment period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kyung Hee University Hospital
Seoul, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul Metropolitan Government Seoul National University Boramae Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, South Korea
-
Seoul National University Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.